Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
Outlook Therapeutics, Inc is a biotechnology business based in the US. Outlook Therapeutics shares (OTLK) are listed on the NASDAQ and all prices are listed in US Dollars. Outlook Therapeutics employs 14 staff and has a trailing 12-month revenue of around USD$5.9 million.
|Latest market close||USD$1.15|
|52-week range||USD$0.499 - USD$1.73|
|50-day moving average||USD$0.9328|
|200-day moving average||USD$1.0449|
|Wall St. target price||USD$5.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.886|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||-4.96%|
|1 month (2020-11-06)||40.24%|
|3 months (2020-09-04)||76.92%|
|6 months (2020-06-05)||-3.36%|
|1 year (2019-12-06)||3.60%|
|2 years (2018-12-06)||88.52%|
|3 years (2017-12-06)||-19.01%|
|5 years (2015-12-02)||N/A|
|Revenue TTM||USD$5.9 million|
|Gross profit TTM||USD$-15,659,128|
|Return on assets TTM||-60.44%|
|Return on equity TTM||-737.24%|
|Market capitalisation||USD$152.6 million|
TTM: trailing 12 months
There are currently 2.8 million Outlook Therapeutics shares held short by investors – that's known as Outlook Therapeutics's "short interest". This figure is 13.9% down from 3.2 million last month.
There are a few different ways that this level of interest in shorting Outlook Therapeutics shares can be evaluated.
Outlook Therapeutics's "short interest ratio" (SIR) is the quantity of Outlook Therapeutics shares currently shorted divided by the average quantity of Outlook Therapeutics shares traded daily (recently around 824376.85459941). Outlook Therapeutics's SIR currently stands at 3.37. In other words for every 100,000 Outlook Therapeutics shares traded daily on the market, roughly 3370 shares are currently held short.
However Outlook Therapeutics's short interest can also be evaluated against the total number of Outlook Therapeutics shares, or, against the total number of tradable Outlook Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Outlook Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Outlook Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0263% of the tradable shares (for every 100,000 tradable Outlook Therapeutics shares, roughly 26 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Outlook Therapeutics.
Find out more about how you can short Outlook Therapeutics stock.
We're not expecting Outlook Therapeutics to pay a dividend over the next 12 months.
Outlook Therapeutics's shares were split on a 1:8 basis on 18 March 2019. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Outlook Therapeutics shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Outlook Therapeutics shares which in turn could have impacted Outlook Therapeutics's share price.
Over the last 12 months, Outlook Therapeutics's shares have ranged in value from as little as $0.499 up to $1.73. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Outlook Therapeutics's is -0.0639. This would suggest that Outlook Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Outlook Therapeutics has bucked the trend.
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was founded in 2010 and is headquartered in Cranbury, New Jersey.
Everything we know about the Loha Co. IPO, plus information on how to buy in.
Everything we know about the Stem Inc IPO, plus information on how to buy in.
Everything we know about the View Inc IPO, plus information on how to buy in.
Everything we know about the Chime IPO, plus information on how to buy in.
Steps to owning and managing WPRT, with 24-hour and historical pricing before you buy.
Steps to owning and managing WBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing WLK, with 24-hour and historical pricing before you buy.
Steps to owning and managing WDC, with 24-hour and historical pricing before you buy.
Steps to owning and managing WAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing VSAT, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.